SCHEMBL26613752

SCHEMBL26613752

Cc1c(Cc2cccc(Br)c2F)c(=O)oc2cc(Oc3ncccn3)ccc12

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP2K1 Q02750 12/20 0.71
RAF1 P04049 10/20 0.71
CYP2C9 P11712 2/20 0.71
CYP3A4 P08684 1/20 0.71
BRAF P15056 2/20 0.67
MAP2K2 P36507 1/20 0.67
MAP2K5 Q13163 1/20 0.67
POLB P06746 1/20 0.49
MIF P14174 1/20 0.49
CTDSP1 Q9GZU7 1/20 0.49
ALDH1A1 P00352 4/20 0.48
KDM4E B2RXH2 3/20 0.48
HSD17B10 Q99714 2/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
GAA P10253 1/20 0.47
HPGD P15428 1/20 0.47
MAOB P27338 2/20 0.45
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ALDH1A2 O94788 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30615225 1.00 MAP2K1 (0.71) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL29842959 0.89 MAP2K1 (0.71) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL965293 0.89 MAP2K1 (0.71) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL26997739 0.87 MAP2K1 (0.77) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL960480 0.85 MAP2K1 (0.67) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL29425523 0.85 MAP2K1 (0.67) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL959547 0.85 MAP2K1 (0.72) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL959413 0.84 MAP2K1 (0.69) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL12694075 0.84 MAP2K1 (0.82) MAP2K1RAF1CYP2C9CYP3A4BRAF
SCHEMBL962160 0.83 MAP2K1 (0.85) MAP2K1RAF1CYP2C9CYP3A4BRAF

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250289811-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. 2025-09-18 US disclosed
WO-2023211812-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS NESTED THERAPEUTICS, INC. (US) 2023-11-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289811-A1 HETEROCYCLIC DERIVATIVES AS MITOGEN-ACTIVATED PROTEIN KINASE (MEK) INHIBITORS MAPK1, MAP3K1, MAPK3 MAP2K1 44/4885RAF1 42/4885CYP2C9 847/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.